

Subject: Hematopoietic Stem Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Disorders		Original Effective Date: 6/26/13
Policy Number: MCP-143	Revision Date(s): 6/2/15, 9/21/16, 12/10/19	
Review Date: 12/16/15, 9/19/17, 7/10/18, 12/10/19, 12/9/20		
MCPC Approval Date: 7/10/18, 12/10/19, 12/9/20		

Contents

Disclaimer	1
Description of Procedure/Service/Pharmaceutical	1
Clinical Criteria	2
Continuation of Therapy	6
Limitations	7
Summary of Medical Evidence	7
Professional Society Guidelines	9
Coding Information	9
Resource References	11
REVIEW/REVISION HISTORY:	14

DISCLAIMER

his Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members.¹

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL

Aplastic Anemia

Aplastic anemia (AA) also called hypoplastic anemia, is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow and can be acquired or congenital. The most common causes of acquired aplastic anemia include idiopathic (no known cause), hepatitis, drugs, chemical toxins, pregnancy, pure red cell anemia, paroxysmal nocturnal hemoglobinuria and parovirus B19. Congenital aplastic anemia usually is caused by genetic mutations in the hTR gene or a rare autosomal recessive inherited disease (Fanconi anemia). Affected patients generally present with recurrent infections due to neutropenia, bleeding episodes due to thrombocytopenia, and fatigue due to anemia. The diagnosis of AA is established following bone marrow aspiration and biopsy. Aplastic anemia is classified as non-severe (NSAA), severe (SAA) and very severe based on the degree of the peripheral blood cytopenias.

Stem Cell Transplantation

Stem-cell transplantation refers to transplantation of hematopoietic stem cells (HSCs) from a donor into a patient. HSCs are immature cells that can develop into any of the three types of blood cells (red cells, white cells or platelets). HSCs are created in the bone marrow and are found in the bone marrow and peripheral blood. There is also a high concentration of HSCs in umbilical-cord blood. Hematopoietic stem-cell transplantation (HSCT) can be either autologous (using the person's own stem cells) or allogeneic (using stem cells from a donor). In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA) type that is identical to the recipient. Matching is performed on the basis of variability at three or more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). As HLA variability increases, transplant-related morbidity and mortality, including graft rejection and graft-versus-host disease, also increase.

Allogeneic HSCT from a human leukocyte antigen (HLA)-matched sibling donor can provide curative therapy for individuals with SAA. It is considered a standard of care for individuals younger than 50 years of age, despite treatment-related morbidity and mortality. Older individuals and those without HLA-identical related donors generally receive first-line therapy with immunosuppressive drugs. Alternative donor transplantation may be an option in children who do not have a matched donor. For patients who lack an HLA-matched sibling, alternative sources of donor grafts include suitably HLA-matched unrelated donors, or HLA-haploidentical, related donors.

CLINICAL CRITERIA 1 2 3-32-35 36-43

All transplants require prior authorization from the Corporate Transplant Department. Solid organ transplant requests will be reviewed by the Corporate Senior Medical Director or qualified clinical designee. All other transplants will be by the Corporate Senior Medical Director or covering Medical Director. If the criteria are met using appropriate NCD and/or LCD guidelines, state regulations and/or MCP policies the Corporate Senior Medical Director's designee can approve the requested transplant.

Members must meet UNOS/OPTN policies and guidelines for pretransplantation evaluation and listing criteria and the diagnosis must be made by a Specialist in the Disease and or Transplant Surgeon.

Pre-Transplant Evaluation: Please see MCP-323 Pre-Transplant Evaluation for additional criteria and information.

Criteria for transplant evaluation include all of the following: ³³⁻³⁹

- ☐ History and physical examination
- ☐ Psychosocial evaluation and clearance:
 - No behavioral health disorder by history or psychosocial issues:
 - if history of behavioral health disorder, no severe psychosis or personality disorder
 - mood/anxiety disorder must be excluded or treated
 - member has understanding of surgical risk and post procedure compliance and follow-up required
 - Adequate family and social support
- ☐ EKG
- ☐ Chest x-ray
- ☐ Cardiac clearance in the presence of any of the following:
 - chronic smokers
 - > 50 years age
 - those with a clinical or family history of heart disease or diabetes
- ☐ Pulmonary clearance if evidence of pulmonary artery hypertension (PAH) or chronic pulmonary disease
- ☐ Performance Status ⁴: [ONE]
 - Karnofsky score 70-100%
 - Eastern Cooperative Oncology Group (ECOG) grade 0-2
- ☐ Neurological exam and clearance for transplant: [ONE]
 - Normal exam by H&P
 - Abnormal neurological exam with positive findings: [ONE]
 - Lumbar puncture normal cytology
 - Lumbar puncture with cytological exam abnormal: CNS disease treated prior to clearance
- ☐ Lab studies:
 - *Complete blood count, Kidney profile (blood urea nitrogen, creatinine), electrolytes, calcium, phosphorous, albumin, liver function tests, Coagulation profile (prothrombin time, and partial thromboplastin time)
 - *Serologic screening for HIV, Epstein Barr virus (EBV), Hepatitis virus B (HBV), and Hepatitis C(HCV), cytomegalovirus (CMV), RPR and/or FTA:
 - If HIV positive all of the following are met:
 - CD4 count >200 cells/mm-3 for >6 months
 - HIV-1 RNA undetectable
 - On stable anti-retroviral therapy >3 months
 - No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioides mycosis, resistant fungal infections, Kaposi's sarcoma, or other neoplasm)
 - If abnormal serology need physician plan to address and/or treatment as indicated
 - UDS (urine drug screen) if patient is current or gives a history of past drug abuse

- ☐ *Colonoscopy (if indicated or if patient is $50 \geq$ older should have had an initial screening colonoscopy, after initial negative screening requires follow up colonoscopy every ten years) with complete workup and treatment of abnormal results as indicated
- ☐ *GYN examination with Pap smear for women ≥ 21 to ≤ 65 years of age or indicated (not indicated in women who have had a TAH or TVH) with in the last three year with complete workup and treatment of abnormal results as indicated

Within the last 12 months:

- ☐ Dental examination or oral exam showing good dentition and oral care or no abnormality on panorex or plan for treatment of problems pre or post-transplant
- ☐ *Mammogram (if indicated or > 40) with complete workup and treatment of abnormal results as indicated
- ☐ *PSA if history of prostate cancer or previously elevated PSA with complete workup and treatment of abnormal results as indicated

**Participating Centers of Excellence may waive these criteria*

Criteria for Transplantation:

1. **Hematopoietic Allogeneic stem-cell transplantation (HSCT)** is considered medically necessary and may be authorized in adults and children who have a fully matched-HLA sibling donor OR, haploidentical related donor when there are no matched sibling or unrelated donors (sharing a haplotype; having the same alleles at a set of closely linked genes on one chromosome)³³⁻³⁵ for the treatment of bone marrow failure syndrome when ALL of the following criteria are met:

- ☐ All pre-transplant criteria are met; and
- ☐ Must be < 60 years of age;
- ☐ Must have a diagnosis of aplastic anemia (includes congenital and acquired) defined as:
 - Severe aplastic anemia (SAA) : [ONE]
 - ◇ A marrow biopsy showing less than 25 percent of normal cellularity; OR
 - ◇ A marrow showing less than 50 percent normal cellularity in which fewer than 30 percent of the cells are hematopoietic and at least two of the following are present:
 - [TWO]
 - absolute reticulocyte count $< 40,000/\text{microL}$;
 - absolute neutrophil count (ANC) $< 500/\text{microL}$;
 - platelet count $< 20,000/\text{microL}$

OR

- Very severe aplastic anemia (vSAA) defined as:
 - ◇ the ANC is $< 200/\text{microL}$

OR

- ☐ Any of the following rare bone marrow failure disorders:
 - Diamond-Blackfan anemia (DBA)
 - Fanconi's anemia (FA)

- Schwachman-Diamond syndrome (SDS)
- Pure red cell aplasia
- Paroxysmal nocturnal hemoglobinuria
- Congenital amegakaryocytic thrombocytopenia (CAMT)
- Dyskeratosis congenital

And must meet age criteria for Aplastic Anemia Diagnosis:

- ☐ For age < 50 years: [ALL]
 - Stem cells are obtained from bone marrow
- ☐ For age >50 years : [ALL]
 - Failed at least one course of immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin;
 - Stem cells are obtained from bone marrow

2. **Hematopoietic Allogeneic stem-cell transplantation (HSCT)** is considered medically necessary and may be authorized in adults and children who have a matched unrelated donor (MUD) for the treatment of bone marrow failure syndrome when ALL of the following criteria are met: [ALL]

- ☐ All pre-transplant criteria are met; and
- ☐ Must be <60 years old;
- ☐ Failed at least one course of immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin; and
- ☐ Stem cells are obtained from bone marrow; and
- ☐ Must have aplastic anemia (includes congenital and acquired) defined as:
 - Severe aplastic anemia: [ONE]
 - ◇ A marrow biopsy showing less than 25 percent of normal cellularity; OR
 - ◇ A marrow showing less than 50 percent normal cellularity in which fewer than 30 percent of the cells are hematopoietic and at least two of the following are present: [TWO]
 - absolute reticulocyte count <40,000/microL;
 - absolute neutrophil count (ANC) <500/microL;
 - platelet count <20,000/microL.

OR

- Very severe aplastic anemia defined as:
 - ◇ the ANC is <200/microL

AND

- ☐ The requesting transplant recipient should not have any of the following **absolute contraindications**:

- Cardiac, pulmonary, and nervous system disease that cannot be corrected and is a prohibitive risk for surgery
 - Malignant neoplasm with a high risk for reoccurrence, non-curable malignancy (excluding localized skin cancer)
 - Systemic and/or uncontrolled infection
 - AIDS (CD4 count < 200cells/mm³)
 - Unwilling or unable to follow post-transplant regimen
 - ◇ Documented history of non-compliance
 - ◇ Inability to follow through with medication adherence or office follow-up
 - Chronic illness with one year or less life expectancy
 - Limited, irreversible rehabilitation potential
 - Active untreated substance abuse issues, requires documentation supporting free from addiction for minimally 6 months if previous addiction was present
 - No adequate social/family support
- ❑ The requesting transplant recipient should be evaluated carefully and potentially treated if the following **relative contraindications** are present:
- Irreversible lung disease patients require consultation and clearance by a Pulmonologist prior to consideration of transplantation, this includes the following:
 - Smoking, documentation supporting free from smoking for 6 months
 - Active peptic ulcer disease
 - Active gastroesophageal reflux disease
 - CVA with long term impairment that is not amendable to rehabilitation or a patient with CVA/transient ischemic attack within past 6 months
 - Obesity with body mass index of >30 kg/m² may increase surgical risk
 - Chronic liver disease such as Hepatitis B/C/D, or cirrhosis which increases the risk of death from sepsis and hepatic failure requires consultation by a gastroenterologist or hepatologist
 - Gall bladder disease requires ultrasound of the gall bladder with treatment prior to transplantation

CONTINUATION OF THERAPY

When extension of a previously approved transplant authorization is requested, review using updated clinical information is appropriate.

- ❑ If Molina Healthcare has authorized prior requests for transplantation, the following information is required for medical review: [ALL]
- Presence of no absolute contraindication as listed above;
 - History and physical within the last 12 months;
 - Kidney profile within the last 12 months;
 - Cardiac update if history of cardiac disease within two years (\geq 50 years of age);
 - Psychosocial evaluation or update within the last 12 months;
 - Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.
- ❑ If authorized prior requests for transplantation were obtained from another insurer, the following information is required for medical review: [ALL]
- Authorization letter/documentation from previous insurer;

- Presence of no absolute contraindication as listed above;
- History and physical within the last 12 months;
- Cardiac update if history of cardiac disease within two years (≥ 50 years of age);
- Psychosocial evaluation or update within the last 12 months;
- Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.

LIMITATIONS

1. Allogeneic (ablative or non-myeloablative) stem cell transplantation when the above criteria are not met.
2. Autologous stem cell transplant
3. Umbilical cord blood as a hematopoietic stem cell source is considered investigational due to the lack of sufficient evidence in the peer reviewed published literature.
4. Hematopoietic stem cell collection, storage and freezing for a future unplanned transplant.

SUMMARY OF MEDICAL EVIDENCE⁴⁻³⁵

The published medical evidence and outcomes for hematopoietic stem cell transplantation for aplastic anemia in children and adults in the United States consists of registry data obtained from transplant centers that perform adult and pediatric transplantation and is available from the United Network for Organ Sharing (UNOS) database. Registry data demonstrates graft survival rates and outcomes for stem cell transplantation based on demographic and clinical information.³ Additional relevant studies are outlined below.

A Cochrane review reported by Peinemann et al. (2013, 2014) evaluated the effectiveness and adverse events of first-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared to first-line immunosuppressive therapy in patients with acquired severe aplastic anemia. Three prospective trials involving 302 patients were included in the review. The authors reported that all studies had a high risk of bias due to the study design. The pooled hazard ratio for overall mortality for the transplant group versus the immunosuppressive therapy group was 0.95 ($p = 0.90$, low quality evidence). Overall mortality was not statistically significantly different between the groups. Treatment-related mortality ranged from 20% to 42% for the transplant group and was not reported for the immunosuppressive therapy group (very low quality evidence). Graft failure was 3%-16% for the transplant group and GVHD was from 26%-51%. Neither endpoint was applicable for the immunosuppressive therapy group. No data was reported by individual study authors regarding response and relapse for the transplant group. None of the included studies addressed health-related quality of life. The percentage of the evaluated patients with a Karnofsky performance status score in the range of 71% to 100% was 92% in the transplant group and 46% in the immunosuppressive therapy group. All studies were conducted more than 10 years ago and the authors note that these results may not be applicable to the standard of care of today. Due to limited, low quality data with a high risk of bias, conclusions are not able to be made regarding the comparative effectiveness of first-line allogeneic HSCT with an HLA-matched sibling donor compared with first-line immunosuppressive therapy.^{27 28}

Buchbinder and colleagues (2012) conducted a descriptive analysis of 1718 patient's post-HCT for acquired SAA between 1995 and 2006 that were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT and reported the prevalence and cumulative incidence estimates of late effects for 1-year HCT

survivors with SAA. Of the HCT recipients, 1176 (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% confidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all <3% and did not increase over time. In contrast, for recipients of URD HCT, the cumulative incidence of developing several late effects exceeded 3% by 5 years: gonadal dysfunction 10.5% (95% CI: 7.3-14.3), growth disturbance 7.2% (95% CI: 4.4-10.7), avascular necrosis 6.3% (95% CI: 3.6-9.7), hypothyroidism 5.5% (95% CI: 2.8-9.0), and cataracts 5.1% (95% CI: 2.9-8.0). The authors concluded that the results indicated that all patients undergoing HCT for SAA remain at risk for late effects, must be counseled about, and should be monitored for late effects for the remainder of their lives.²²

Kim et al (2012) retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.²³

In 2011 Peinmann and associates performed a meta-analysis to compare outcomes of first-line matched related donor hematopoietic stem cell transplantation to immunosuppressive therapy in patients with acquired severe aplastic anemia. 26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. No RCTs were identified. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. The review concluded that young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies.¹⁸

Perez-Alburne et al. (2008) analyzed data from 195 children with acquired SAA who underwent unrelated donor transplantation between 1989 and 2003 to determine if unrelated donors provide a source of hematopoietic stem cells in children with severe aplastic anemia (SAA) who fail immunosuppressive therapy and lack a human leucocyte antigen (HLA)-matched sibling donor. Neutrophil recovery (86% at day-28) was

higher with total body irradiation-containing conditioning regimen and in younger recipients (aged < or =16 years) receiving grafts from older donors (aged >40 years). Recovery was lower after mismatched transplants and transplantations prior to 1997. Mortality rates were higher after mismatched transplants, in recipients with a poor performance score, and when the interval between diagnosis and transplantation was longer than 4 years. When restricted to donor-recipient pairs with allele-level HLA typing (8-loci; n = 118), mortality rates were also higher after mismatched transplants and older recipients receiving grafts from older donors; 5-year probabilities of overall survival after HLA-A, -B, -C, -DRB1 matched and mismatched transplants adjusted for donor and recipient age were 57% and 39%, respectively (P = 0.008). The authors concluded that unrelated donor transplantation is an acceptable alternative for children; early referral for transplantation and identification of an HLA-matched (allele-level) donor offers the best outcome. ¹⁴

Allogeneic hematopoietic stem cell transplantation may also be an option under specific circumstances for Diamond-Blackfan anemia (DBA), Fanconi's anemia (FA) and paroxysmal nocturnal hemoglobinuria. In a report from the DBA registry, 20 of 354 registered individuals underwent hematopoietic stem cell transplantation, and the 5-year survival rates were 87.5% when recipients received HLA-identical sibling grafts (Gluckman, 2008). Dufour and colleagues (2008) reported in a summary of allogeneic hematopoietic stem cell transplantation from matched related donors over 6 years in FA, totaling 103 individuals, that overall survival ranged from 83–88%, with transplant-related mortality ranging from 8%–18.5% and average chronic GVHD of 12%. Santarone and colleagues (2010) performed a retrospective study of 26 individuals with paroxysmal nocturnal hemoglobinuria and concluded that hematopoietic stem cell transplantation may lead to a long-term cure rate as high as 60% in a heterogeneous cohort of seriously ill individuals with paroxysmal nocturnal hemoglobinuria. ⁷⁸

Congenital amegakaryocytic thrombocytopenia (CAMT), dyskeratosis congenital, pure red cell aplasia and paroxysmal nocturnal hemoglobinuria are rare bone marrow failure disorders that respond to allogeneic hematopoietic stem cell transplantation. Small studies and case reports have shown favorable outcomes in these disorders. ²⁸⁻³²

PROFESSIONAL SOCIETY GUIDELINES

National Marrow Donor Program (NMDP): The NMDP lists severe aplastic anemia and other bone marrow failure (including Fanconi anemia, Diamond-Blackfan anemia and others) as indications for HSCT. ³⁶

CODING INFORMATION THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

CPT	Description
	Collection Codes
38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38230	Bone marrow harvesting for transplantation; allogeneic

38232	Bone marrow harvesting for transplantation; autologous
	Cell Processing Services
38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage
38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing
38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing
38210	Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion
38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal
38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion
38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion
38215	Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer
	Cell infusion codes
38240	Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic
38241	Bone marrow or blood-derived peripheral stem cell transplantation; autologous
38242	Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic donor lymphocyte infusions
38243	Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic hematopoietic cellular transplant boost

HCPCS	Description
S2140	Cord blood harvesting for transplantation, allogeneic
S2142	Cord blood-derived stem cell transplantation, allogeneic
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including pheresis and cell preparation/storage; marrow ablative therapy; drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days or pre-and post-transplant care in the global definition

ICD-10	Description
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]
D60-D60.9	Acquired pure red cell aplasia (erythroblastopenia)
D61	other aplastic anaemias
D61.0- D61.09	constitutional aplastic anaemia
D61.1	drug-induced aplastic anaemia
D61.2	aplastic anaemia due to other external agents
D61.3	idiopathic aplastic anaemia
D61.8	other specified aplastic anaemias
D61.9	aplastic anaemia, unspecified

Government Agency

1. Centers for Medicare & Medicaid Services. NCD for Stem Cell Transplantation (Formerly 110.8.1) 110.23. Effective date 1/27/2016. Accessed at: <http://www.cms.gov/medicare-coverage-database/>
1. National Bone Marrow Donor Program HLA Matching Requirements. Accessed at: http://marrow.org/Patient/Transplant_Process/Search_Process/HLA_Matching_Finding_the_Best_Donor_or_Cord_Blood_Unit.aspx
2. National Marrow Donor Program. Severe aplastic anemia outcomes. Accessed at: <https://bethematchclinical.org/Transplant-Indications-and-Outcomes/>

Peer Reviewed Publications

3. Eastern Cooperative Oncology Group (ECOG) Performance Status. Accessed at: http://www.ecog.org/general/perf_stat.html
4. Mackinnon S. American Society of clinical Oncology (ASCO). Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation. 2008.
5. Szpecht D, Gorczyńska E, Kałwak K, et al. Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):225-33
6. Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant 2008; 41(suppl 2):S90-95.
7. Gluckman E, Wagner JE. Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome. Bone Marrow Transplant 2008; 41(2):127-132.
8. Guinan E. Diagnosis and Management of Aplastic Anemia. Hematology. December 10, 2011 vol. 2011 no. 1 76-81.
9. Yoshida N, Yagasaki H et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematol. May 1, 2011 vol. 96 no. 5 771-774.
10. Peinemann F, Ulrich G et al. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematol December 1, 2009 vol. 94 no. 12 1732-1742.
11. Passweg J, Marsh J. Aplastic Anemia: First-line Treatment by Immunosuppression and Sibling Marrow Transplantation. ASH Education Book December 4, 2010 vol. 2010 no. 1 36-42.
12. Sangiolo D, Storb R, Deeg HJ, et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant 2010; 16:1411.
13. Perez-Albuerne ED, Eapen M, Klein J, Gross TJ, Lipton JM, Baker JS, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008 Apr;141(2):216-23. Epub 2008 Feb 26.
14. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007 Feb 1.
15. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec;12(12):1277-84.
16. DeZern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011 Apr;4(2):221-30.

17. Peinmann F, Grouvan U et al. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. *PLoS One*. 2011 Apr 25 ;6(4):e18572.
18. Scheinberg P, Nunez O, Weinstein B. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *N Engl J Med*. 2011 Aug 4;365(5):430-8. doi: 10.1056/NEJMoa1103975.
19. Scheinberg P, Young NS. How I treat acquired aplastic anemia. *Blood*. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19.
20. Kikuchi A, Yabe H, Kato K et al. Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan. *Bone Marrow Transplant*. 2013 May;48(5):657-60. doi: 10.1038/bmt.2012.205. Epub 2012 Oct 29.
21. Buchbinder D, Nugent DJ, Brazauskas R, Wang Z et al. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2012 Dec;18(12):1776-84. doi: 10.1016/j.bbmt.2012.06.018. Epub 2012 Aug 1.
22. Kim H, Lee KH, Yoon SS, Sohn SK et al. Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia. *Biol Blood Marrow Transplant*. 2012 Oct;18(10):1500-8. doi: 10.1016/j.bbmt.2012.03.015. Epub 2012 Apr 1.
23. Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. *Haematologica*. 2010 December; 95(12):2119.
24. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. *Blood*. 2011 Sep 1;118(9):2618-21. doi: 10.1182/blood-2011-05-354001. Epub 2011 Jun 15.
25. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. *Autoimmun Rev*. 2014; 13(4-5):569-573.
26. Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. *Cochrane Database Syst Rev*. 2013 Jul 23;7:CD006407.
27. Peinemann F, Labeit AM. Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review. *BMJ Open*. 2014 Jul 15;4(7):e005039.
28. Dietz AC, Orchard PJ, Baker KS, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. *Bone Marrow Transplant*. 2011; 46(1):98-104.
29. Gadalla SM, Sales-Bonfim C, Carreras J, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. *Biol Blood Marrow Transplant*. 2013; 19(8):1238-1243.
30. Frangoul H, Keates-Baleeiro J, Calder C, et al. Unrelated bone marrow transplant for congenital amegakaryocytic thrombocytopenia: report of two cases and review of the literature. *Pediatr Transplant*. 2010; 14(4):E42-45.
31. Woods G, Bajwa RP, Rose MJ. Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature. *Pediatr Transplant*. 2014; 18(1):E31-34.
32. Bizzetto R, Bonfim C, Rocha V, et al.; Eurocord and SAA-WP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. *Haematologica*. 2011; 96(1):134-141.

33. XZhang Y, Guo Z et al. Comparison of haploidentical hematopoietic stem cell transplantation and immunosuppressive therapy for the treatment of acquired severe aplastic anemia in pediatric patients. *American Journal of Therapeutics*. 2017;24(2):e196-e201.
34. Dezern A, Brodsky R. Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia. *Hematol Oncol Clin North Am*. 2018 Aug; 32(4): 629–642.
35. Xu LP, Jin S et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. *J Hematol Oncol*. 2017 Jan 21;10(1):25.

Professional Society Guidelines

36. National Marrow Donor Program® (NMDP) and the American Society for Blood and Marrow Transplantation (ASBMT) referral guidelines: Recommended Timing for Transplant Consultation. Accessed at: <https://bethematchclinical.org/Transplant-Indications-and-Outcomes/Referral-Timing-Guidelines/>
37. National Marrow Donor Program® (NMDP). Patient Eligibility for HCT. Accessed at: <https://bethematchclinical.org/Transplant-Indications-and-Outcomes/Eligibility/>
38. Choosing Wisely Canada: Don't routinely use peripheral blood stem cells for patients with aplastic anemia when a suitable bone marrow donor is available due to a higher risk of graft-versus-host disease. *Blood and Marrow Transplant. Five Things Physicians and Patients Should Question: American Society for Blood and Marrow Transplantation Canadian Blood and Marrow Transplant Group Dec, 2017*. Accessed at: <https://choosingwiselycanada.org/wp-content/uploads/2018/01/Blood-and-Marrow-EN.pdf>
39. Latour R, Peters C, Gibson B et al. European Group for Blood and Marrow Transplantation (EBMT). Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. June 2015. Accessed at: <https://www.nature.com/articles/bmt2015117>
40. Cancer Care Ontario (CCO): Consensus pathology recommendations for complex malignant hematology Guidelines. Dec, 2016. Accessed at: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/43061>

Other Resources

41. Dynamed. Plus [Internet]. Ipswich (MA): EBSCO Information Services. 1995-2020. Aplastic Anemia.
42. Hayes Clinical Research Support. Aplastic Anemia Pretransplant Evaluation Criteria. Winifred Hayes Inc. May 24, 2013
43. UpToDate: Waltham, MA: Walters Kluwer Health; 2020
 - Deeg HJ, Sandmaier B. Determining eligibility for allogeneic hematopoietic cell transplantation. 2016.
 - Negrin R. Hematopoietic cell transplantation in aplastic anemia in adults.
 - Kahn S, Negrin R. Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children and adolescents.
 - Schrier S. Aplastic anemia: Prognosis and treatment.
 - Schrier S, Bertuch A. Acquired aplastic anemia in children and young adults.
 - Rogers Z. Shwachman-Diamond syndrome.
 - Fuchs E, Luznik L. HLA-haploidentical hematopoietic cell transplantation.
44. Advanced Medical Review:
 - Policy reviewed by practicing MD board certified in Internal Medicine, Oncology and Hematology, 2013.
 - Policy reviewed by practicing MD board certified in Oncology, Hematology. 11/8/19.

REVIEW/REVISION HISTORY:

6/26/13: New Policy

6/2/15: This policy was updated with new pretransplant criteria.

9/21/16: The medical necessity criteria was reviewed and updated to include the following disorders: Diamond-Blackfan anemia (DBA) Fanconi's anemia (FA) and Schwachman-Diamond syndrome (SDS). Professional guidelines and reference sections were updated.

9/19/17: Policy reviewed, no changes

7/10/18: Policy reviewed, no changes

12/10/19: The policy was reviewed and updated to include the following disorders: Pure red cell aplasia, Paroxysmal nocturnal hemoglobinuria, congenital amegakaryocytic thrombocytopenia (CAMT), Dyskeratosis congenita. Updated guidelines, coding and references sections. Clarified that haploidentical transplants may be considered medically necessary when there are no matched sibling or unrelated donors.

12/9/20: Policy reviewed, no changes.